Treatment for basal cell carcinoma

• US 20080119572A1
• Filed: 01/15/2008
• Published: 05/22/2008
• Est. Priority Date: 03/25/2003
• Status: Active Grant

• Current Assignee: Medicis Pharmaceutical Corporation (Bausch Health Cos., Inc.)
• Original Assignee: Graceway Pharmaceuticals LLC (Bausch Health Cos., Inc.)
• Inventors: Fox, Terrance, Ginkel, Angela, Owens, Mary
• Granted Patent: US 7,696,159 B2
• Time in Patent Office: Days
• US Class Current: 514/789
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: A61K 47/12 Carboxylic acids; Salts or anhydrides thereof
• CPC Class Codes: A61K 9/0014 Skin, i.e. galenical aspects of topical compositions non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

The present invention provides a method of treating basal cell carcinoma in a subject. Generally, the method includes administering to the subject an amount of IRM compound effective for treating basal cell carcinoma in a treatment cycle that includes at least two consecutive days in which the IRM compound is administered and at least one day in which the IRM compound is not administered.

Claims

1. A method of treating basal cell carcinoma in a subject, the method comprising administering to the subject an amount of an IRM compound effective for treating basal cell carcinoma, wherein the IRM compound is administered in a treatment cycle that comprises at least two consecutive days in which the IRM compound is administered and at least one day in which the IRM compound is not administered.

2. The method of claim 1 wherein the treatment cycle comprises at least five days in which the IRM compound is administered.

3. The method of claim 2 wherein the treatment comprises at least five consecutive days in which the IRM compound is administered.

4. The method of claim 1 wherein the treatment cycle comprises at least two consecutive days in which the IRM compound is not administered.

5. The method of claim 1 wherein the treatment cycle comprises five days in which the IRM compound is administered and at least two days in which the IRM compound is not administered.

6. The method of claim 5 wherein the five days are five consecutive days.

7. The method of claim 1 wherein the method comprises at least two treatment cycles.

8. The method of claim 7 wherein the method comprises at least six treatment cycles.

9. The method of claim 1 wherein administering the IRM compound comprises applying one dose of the IRM compound per day.

10. The method of claim 1 wherein administering the IRM compound comprises topically applying the IRM compound to a treatment area that includes a lesion.

11. The method of claim 10 wherein the IRM compound is applied in a formulation that comprises from about 1% to about 10% IRM compound.

12. The method of claim 11 wherein the formulation comprises about 5% IRM compound.

13. The method of claim 11 wherein the formulation is applied to the treatment area for from about two hours to about 24 hours.

14. The method of claim 13 wherein the formulation is applied to the treatment area for from about six hours to about twelve hours.

15. The method of claim 11 wherein the formulation is applied to the treatment area for about eight hours.

16. The method of claim 10 wherein the treatment area further comprises skin at least 0.5 cm beyond the margin of the lesion.